Venture Partners, Executives-in-Residence and Advisors Archives

Eoin McDonnell, PhD

Eoin joined Pappas Capital in 2026 as an Executive-in-Residence. He is currently Vice President and Head of Functional Genomics at Vividion Therapeutics, a wholly owned subsidiary of Bayer AG. Eoin is responsible for integrating advanced CRISPR-based screening with chemoproteomics to expand the universe of druggable targets and accelerate discovery in oncology and immunology. His work centers on defining causal genetic dependencies and resolving drug-target function at high resolution, then translating those insights into actionable strategies for small-molecule development.

Eoin was CEO and co-founder of Tavros Therapeutics, a North Carolina–based oncology drug discovery company. There he led the build of the next-generation CRISPR functional genomics platforms at the company's core, creating an integrated discovery capability that spanned target identification, mechanism-of-action insights, and small-molecule program advancement. Tavros was acquired by Vividion/Bayer AG in 2024. He was named CEO of the Year by the Triangle Business Journal in 2023, and Tavros was recognized as a Best Place to Work in 2024.

Eoin brings deep experience across oncology drug discovery, company building, and business development, spanning both biotech and large-pharma environments. Prior to Tavros, he worked at Element Genomics where he helped advance CRISPR-based screening technologies, work that continued at UCB Pharma following its acquisition of Element in 2018. Prior to Element he was a postdoctoral fellow at Pfizer where he worked on the CDK4/6 inhibitor Ibrance (palbociclib). He has experience leading a broad range of pharma and biotech partnerships, venture capital fundraising, and M&A.

Education:

Duke University (PhD in Molecular Cancer Biology)

Lisa Dreyer - June 11, 2026 - No Comments

Richard Pascoe

Richard joined Pappas Capital in 2026 as a Senior Advisor. He is currently the Chief Executive Officer of Acertis Pharmaceuticals, a private specialty pharmaceutical company. Prior to Acertis, he was the Executive Chairman and CEO of Zevra Therapeutics, a rare disease company, from 2021 to 2023, CEO of Histogen from 2019 to 2021, CEO of Apricus Biosciences from 2013 to 2019, and CEO of Somaxon Pharmaceuticals (acquired by Pernix Therapeutics) from 2008 to 2019.

Prior to joining Somaxon, Richard held a series of senior management roles including Chief Operating Officer at ARIAD Pharmaceuticals (acquired by Takeda) and Senior Vice President of the Neuroscience Division at King Pharmaceuticals (acquired by Pfizer). Prior to King, Mr. Pascoe held commercial roles in the hospital pharmaceutical and medical device groups at Medco Research, (acquired by King), COR Therapeutics (acquired by Millennium Pharmaceuticals), and B. Braun Interventional.

Richard is currently a member of the board of directors of Prizm Therapeutics, an ultra-rare specialty pharmaceutical company. He formerly served as a member of the board of directors at Seelos Therapeutics and Cohera Medical. He is the past Chairman of the board of directors of Biocom California, the leading advocate for the life sciences industry in California, and is also a member of the board of directors of the Johnny Mac Soldiers Fund, which provides scholarships to the children of our nation’s fallen service members. Richard served on active duty as a commissioned officer with the U.S. Army’s 24th Infantry Division during Operation Desert Storm where he earned the Bronze Star Medal.

Education:

United States Military Academy at West Point (BS in Leadership)

Lisa Dreyer - January 7, 2026 - No Comments

Bruce Sullenger, PhD

Bruce's research program is focused on the discovery and development of novel RNA therapeutics. As a postdoctoral fellow in Tom Cech’s lab, he developed a detailed working knowledge of nucleic acid biochemistry and during his 30 years on the faculty at Duke, he developed one of the pre-eminent academic laboratories exploring the potential utility of nucleic acid aptamers as therapeutic agents. In particular, his group invented novel methods to control the activity of coagulation factors using aptamers and matched antidotes and has translated this invention/discovery into 8 clinical studies with over 2,000 patients including a phase 2 clinical trial evaluating an aptamer against VWF that is currently enrolling ischemic stroke patients. In addition, Bruce has worked closely with the biotechnology and pharmaceutical sectors and has held numerous positions on scientific societies in the nucleic acid therapeutic space. Finally, he is an entrepreneur and founder of five biotechnology companies and has served as a consultant for three large pharmaceutical companies and as an SAB member for several biotechnology companies.

Education:

Indiana University (BS Biology)
Cornell University (PhD Molecular Biology)
University of Colorado (Postdoc Biochemistry)

Lisa Dreyer - February 11, 2025 - No Comments

Charles Gersbach, PhD

Dr. Gersbach is the John W. Strohbehn Distinguished Professor of Biomedical Engineering at Duke University, the Director of the Duke Center for Biomolecular and Tissue Engineering, and the Director of the Duke Center for Advanced Genomic Technologies. His research interests are in genome and epigenome editing, gene therapy, regenerative medicine, biomolecular and cellular engineering, synthetic biology, and genomics. His work has led to new approaches to study genome structure and function, program cell biology, and treat genetic disease. Dr. Gersbach’s work has been recognized through awards including the NIH Director’s New Innovator Award, the NSF CAREER Award, the Outstanding New Investigator Award from the American Society of Gene and Cell Therapy, and induction as a Fellow of the American Institute for Medical and Biological Engineering and member of the National Academy of Inventors. He is also the co-founder of three biotechnology companies and an advisor to several others.

Lisa Dreyer - February 27, 2024 - No Comments

Rodolphe Barrangou, PhD

Dr. Barrangou is the T. R. Klaenhammer Distinguished Professor at North Carolina State University. He is focusing on the characterization of CRISPR-Cas systems and their applications in bacteria. Dr. Barrangou spent 9 years in R&D and M&A at Danisco and DuPont, and has been at NC State since 2013. He has received several international awards, and was elected into the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Inventors. Dr. Barrangou is a co-founder of Intellia Therapeutics, Locus Biosciences, TreeCo, Ancilia Biosciences and CRISPR Biotechnologies, and the Editor in Chief of the CRISPR Journal. He earned a BS in Biological Sciences from Rene Descartes University, France, an MS in Biological Engineering from the University of Technology in Compiegne, France, an MS in Food Science from NC State, a PhD in Genomics from NC State, and an MBA from the University of Wisconsin-Madison.

Lisa Dreyer - February 16, 2024 - No Comments

Donald McDonnell, PhD

Dr. McDonnell is a Glaxo Welcome Professor of Molecular Cancer Biology in the Department of Pharmacology and Cancer Biology at the Duke University School of Medicine, as well as Associate Director of Translational Research at the Duke Cancer Institute. Dr. McDonnell is a translational scientist who employs genetics, biochemistry, and chemical biology to probe the molecular mechanisms underlying the pathobiology of dysregulated hormone signaling in different cancers. His group discovered a new class of medicines (oral Selective Estrogen Receptor Downregulators; SERDs), thirteen of which are currently in clinical trials. Notable was his group’s discovery of Elacestrant (FDA approved January 2023) and Lasofoxifene (Phase III) as treatments for metastatic breast cancer. They are also developing new approaches to target the androgen signaling axis in metastatic castrate resistant prostate cancer. In recent years, his group has embarked on a major effort to understand how sex hormones impact tumor immunity through their ability to regulate immune cell repertoire and function. The clinical translation of insights from this work is a current focus of the group’s efforts. Dr. McDonnell and his team have also had a longstanding interest in defining the mechanisms by which hypercholesterolemia and dyslipidemia impact cancer biology. This research has been funded continuously for 33 years by the NCI/NIH, the Prostate Cancer Foundation, the Komen Foundation, and the Department of Defense. Dr. McDonnell is a recipient of a DOD Breast Cancer Innovator Award and is a Komen Scholar. He is a Member of the National Academy of Medicine and the National Academy of Inventors.

Lisa Dreyer - February 16, 2024 - No Comments

Manesh Patel, MD

Dr. Patel is Chief of the Division of Cardiology and Director of the Duke Heart Center. His clinical interests include diagnostic and interventional coronary angiography, peripheral angiography and percutaneous intervention. His research interest in therapies for athero-thrombosis in the coronary and peripheral vascular arteries has been highlighted by leading several multi-center PCI trials. He also led the Peripheral Academic Research Consortium (PARC) on peripheral artery definitions and is working on defining and improving patient outcomes with cardiovascular disease. In 2016, he was elected to the American Society of Clinical Investigation (ASCI). In 2020, Dr. Patel was named the endowed Distinguished Richard S. Stack Professor. In 2022, he received the Duke School of Medicine Career Mentoring Award, and was named the Ron Stoney Vascular Hero by Vascular Cures, a non-profit patient organization aimed at improving vascular health. In 2023, Dr. Patel was named the AHA Physician of the year. Dr. Patel has published over 400 peer-reviewed articles in high impact journals and has been named in the top 1% of cited researchers by Clarivate Analytics. Dr. Patel received his medical degree from Emory University School of Medicine in 1997. He completed his residency at Duke in 2000, followed by fellowships in cardiology and interventional cardiology at Duke University and a clinical research fellowship at the Duke Clinical Research Institute.

Lisa Dreyer - February 15, 2024 - No Comments

William Pay

William joined Pappas Capital in 2023 as a Venture Partner. Prior to joining Pappas, he was the Founding Managing Director for Asia at Bryan Garnier & Co., a leading European boutique investment bank headquartered in Paris with over 180 bankers. In this role, he specialized in advising mid-cap, high-growth, and disruptive companies.

William has served for many years as an advisor to EPS Holdings, one of the largest privately held clinical CROs headquartered in Tokyo, Japan. He also holds an advisory position serving the Chairman of Hong Kong WinHealth Pharma Group, a prominent pharmaceutical company focused on commercialization of rare diseases and specialty pharmaceuticals in the Greater China region.

Before transitioning to the investment sector, William’s last corporate role was with Bayer Healthcare in the Far East as the Chief of Strategic Sourcing. He led a cross-category strategic sourcing and quality compliance team, managing a volatile supply chain with an annual spend of half a billion euros. Prior to joining Bayer in July 2012, William held various globally-based strategic sourcing and business development/sales marketing positions of increasing responsibility at Takeda (Singapore), Johnson & Johnson (California), and Pfizer (NYC and Madrid) on the buy side, and for PPD (then part of the Carlyle Group and now part of Thermo Fisher) and Quintiles Transnational (now rebranded as IQVIA) on the supply side. His career has spanned over 25 years across Singapore, the US, Europe, and China.

William is a member of the BayHelix Group, a non-profit professional organization of business leaders from the investment and health-tech communities. The group’s mission is to shape the growth of the life science industry, foster business collaborations, and share information and career experiences among its members. Educated in both China and the US, William is based in Wuxi near Shanghai. He is fluent in English and Mandarin Chinese.

Lisa Dreyer - October 20, 2022 - No Comments

Richard Staub

Richard joined Pappas Capital in 2022 as a Venture Partner and is currently the President of R&D Solutions at IQVIA. Supported by high-powered information and technology assets, the clinical experts in R&D Solutions leverage comprehensive evidence-driven trial design, accelerate site activation and patient recruitment, and optimize trial execution. Richard also serves as chair of the R&D Solutions Executive Committee. Prior to his role as President of IQVIA's R&D Solutions business unit, Richard was president of Novella Clinical, a specialty clinical research organization acquired by Quintiles in 2013, and the leader of QuintilesIMS’s Global Functional Resourcing business. Richard joined Novella in 2004 and served as president and CEO from 2008-2013. Under his leadership, Novella became a distinctively agile, results oriented CRO in the highly complex and fast-growing areas of specialty pharma and medical technology. Prior to Novella, Richard was senior vice president of global business development for one of the world’s largest CROs. His career in the pharmaceutical industry began at Zeneca Pharmaceuticals in 1989, where he was given increasing responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager.

Education:

University of North Carolina at Chapel Hill (BA in Economics)

Lisa Dreyer - October 11, 2022 - No Comments

Catherine Yue, PhD

Catherine joined Pappas Capital in 2022, covering deal sourcing, investment opportunity evaluation, due diligence and network building in Singapore, Hong Kong and Mainland China. She brings to the Pappas team a strong understanding of the start-up ecosystem in Asia based on her deep tech experience as an entrepreneur, start-up ecosystem builder, and angel investor. Catherine started her career as an engineering specialist for a state-owned utilities company, supporting technical and commercial operations and cross-border transactions in both Singapore- and China-based companies. Catherine is an ESG advocate and received a Certificate in ESG Investing from the CFA Institute.

Education:
National University of Singapore (B.Eng in Environmental Engineering)
National University of Singapore (PhD in Environmental Engineering)

Lisa Dreyer - September 22, 2022 - No Comments